Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Conditions:   Solid Tumor;   Hepatocellular Carcinoma;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Vorolanib;   Drug: Nivolumab;   Drug: Pembrolizumab;   Procedure: Peripheral blood draw
Sponsors:   Washington University School of Medicine;   Xcovery Holding Company, LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 30, 2019 / by / in
Comments